BioRestorative Therapies, Inc. (BRTX)
| Market Cap | 8.36M |
| Revenue (ttm) | 128,500 |
| Net Income (ttm) | -17.67M |
| Shares Out | 4.67M |
| EPS (ttm) | -4.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 65,473 |
| Open | 1.65 |
| Previous Close | 1.58 |
| Day's Range | 1.60 - 1.94 |
| 52-Week Range | 1.41 - 7.13 |
| Beta | 60.86 |
| Analysts | Strong Buy |
| Price Target | 10.50 (+486.59%) |
| Earnings Date | Nov 13, 2023 |
About BRTX
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase ... [Read more]
Financial Performance
In 2022, BRTX's revenue was $119,800, an increase of 160.43% compared to the previous year's $46,000. Losses were -$18.49 million, -58.25% less than in 2021.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for BRTX stock is "Strong Buy." The 12-month stock price forecast is $10.5, which is an increase of 486.59% from the latest price.
News
Roth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says “Low Valuation Undeserved”
MELVILLE, NY / ACCESSWIRE / September 18, 2023 / BioRestorative Therapies Inc. (NASDAQ:BRTX) ("BioRestorative") is a clinical-stage biotech company that is developing cell-based therapies to treat chr...
BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics
-- BioRestorative to Leverage its Core Competencies in Cell Biology and Manufacturing to S upply B iologics for C osmetic A pplications in Strategic Agreement
BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease
--Site activation allows for patients in the S tate of New York to participate in the BRTX-100 t rial —
As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs
MELVILLE, NY / ACCESSWIRE / August 30, 2023 / Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to experts, up to 80% of the populati...
BioRestorative Therapies Gains Additional Investor Confidence As Insider Dale Broadrick, CEO Lance Alstodt Purchase Thousands of Shares
MELVILLE, NY / ACCESSWIRE / August 2, 2023 / Valuations, competitive landscape and market opportunity are fundamental characteristics in evaluating investment decisions. Insider buying - the "smart mo...
Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform - Insights From The Discussion
MELVILLE, NY / ACCESSWIRE / July 31, 2023 / Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to the National Institute of Neurologic...
Insider Buying Alert: Lance Alstodt Acquires 4200 Shares of BioRestorative Therapies Inc (BRTX)
On July 25, 2023, Lance Alstodt, President, CEO, COB, and 10% Owner of BioRestorative Therapies Inc ( BRTX , Financial), made a significant purchase of 4200 shares of the company's stock. This move is...
BioRestorative Therapies (NASDAQ:BRTX) Receives Landmark License From New York State
MELVILLE, NY / ACCESSWIRE / July 21, 2023 / BioRestorative Therapies Inc. (NASDAQ:BRTX) ("BioRestorative"), a clinical-stage company specializing in stem cell-based therapies, has announced that it ha...
BioRestorative Therapies Announces $2.1 Million Registered Direct Offering
MELVILLE, N.Y., July 11, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapi...
BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities
MELVILLE, NY / ACCESSWIRE / July 7, 2023 / BioRestorative Therapies Inc. (NASDAQ:BRTX) has received a unanimous recommendation to proceed in its Phase 2 clinical trial for chronic lumbar disc disease,...
BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes
MELVILLE, N.Y., June 27, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BR T X), a clinical stage company focused on stem cell-based ther...
BioRestorative Therapies, Inc. to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
MELVILLE, NY., June 16, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, announ...
Metabolic Syndrome: The Silent Epidemic On The Rise And How BioRestorative Therapies Inc. Is Helping Fight It
MELVILLE, NY / ACCESSWIRE / June 15, 2023 / Once a lesser-known health condition, now a problem crippling millions of people around the world: metabolic syndrome is unfortunately on the rise. Due to t...
BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease
-- Clinical data expected to be reviewed by independent data safety monitoring board (DSMB) as to initial safety dosing profile of BRTX-100-- MELVILLE, N.Y., June 12, 2023 (GLOBE NEWSWIRE) -- BioRest...
BioRestorative Therapies, Inc. to attend the Jefferies 2023 Healthcare Conference
MELVILLE, NY., June 01, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today...
BioRestorative Therapies Receives License from New York State Department of Health to act as Tissue Bank for Mesenchymal Stem Cell Processing
--License will enable expanded clinical operations for investigator-initiated trials and potential “right to try” uses of BRTX-100.—
BioRestorative Therapies Receives Notice of Allowance by the Japanese Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program
-- Upon issuance , patent will be the fourth Japanese patent to issue for the ThermoStem ® program targeting obesity and metabolic disorders, including type 2 diabetes-- MELVILLE, N.Y., May 15, 2023 ...
A New Era In Regenerative Medicine? BioRestorative Therapies (NASDAQ:BRTX) Reports Leading The Expansion Of The Adipose-Derived Stem Cell Therapy Market
MELVILLE, NY / ACCESSWIRE / May 12, 2023 / Brown Adipose-Derived Stem Cell (BADSC) therapy has emerged as a groundbreaking innovation in regenerative medicine, capturing the attention of scientists, c...
BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Company's Phase 2 Clinical Trial
MELVILLE, N.Y., May 08, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based th...
BioRestorative Therapies, Inc. to participate at the EF Hutton Global Conference May 10-11 in New York City
MELVILLE, NY., May 04, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today ...
BioRestorative Therapies Announces Completion of Patient Enrollment for Safety Run-In Component of its Phase 2 Clinical Study of BRTX-100
-- Clinical data from safety run-in scheduled to be released in second half of 2023 .—
BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100
Bruder Consulting & Venture Group engaged to expand BRTX-100 c linical indication p ipeline
BioRestorative Therapies to Participate at the 35th Annual ROTH MKM Conference on March 12 -14, 2023
Melville, NY., March 07, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the "Company") (Nasdaq: BRTX), a clinical stage company focused on the development of first-in-cla...
BioRestorative Therapies Receives Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program
--Notice of allowance will be the third US patent to issue from this ThermoStem ® family targeting obesity and metabolic disorders, including type 2 diabetes-- MELVILLE, N.Y., March 02, 2023 (GLOBE NE...
BioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem® Program
-- Patent provides protection in key international markets for BioRestorative ' s ThermoStem ® program targeting obesity and metabolic disorders, including type 2 diabetes -- MELVILLE, N.Y., Feb. 08, ...